NDAORALTABLETPriority Review
Approved
Nov 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
21
Data completeness
7/8 — Comprehensive
Priority Review
LIVTENCITY (maribavir) by Takeda is cytomegalovirus pul97 kinase inhibitors [moa]. Approved for cytomegalovirus pul97 kinase inhibitor [epc]. First approved in 2021.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIVTENCITY (maribavir) is an oral small-molecule cytomegalovirus (CMV) pUL97 kinase inhibitor approved in November 2021 for treatment-resistant CMV infection. It represents a novel mechanism of action targeting viral protein kinase pUL97, which is essential for CMV replication and resistance to standard antivirals. This drug addresses a critical unmet need in immunocompromised patients who have failed conventional CMV therapies.
$37MPart D
Peak17.3 years to LOEEarly-stage peak sales with modest Part D claims (~1,458 in 2023) indicate a niche specialist market with stable commercial team sizing focused on targeted healthcare provider engagement.
Mechanism of Action
Cytomegalovirus pUL97 Kinase Inhibitors
Pharmacologic Class:
Cytomegalovirus pUL97 Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
Started Nov 2025
10 enrolled
Cytomegalovirus (CMV)Kidney DiseaseKidney Failure
A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium
Started Feb 2025
75 enrolled
Cytomegalovirus (CMV)
A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
Started Dec 2024
20 enrolled
Cytomegalovirus (CMV)
A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea
Started Nov 2024
168 enrolled
Cytomegalovirus (CMV)
A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection
Started Oct 2024
265 enrolled
Cytomegalovirus (CMV)
Worked on LIVTENCITY at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.